The FDA’s own scientists just flagged the peptides it’s about to review

The honest read on peptides — recovery, midlife, and beyond. What the evidence supports, what it doesn’t, and what’s just good marketing.

What is a peptide, actually?

A peptide is just a short chain of amino acids — the same building blocks that make up proteins, only smaller. Your body makes thousands of them; they act as signals, telling cells what to do. That’s it. That’s the whole category.

Which is exactly why the word tells you so little. “Peptide” describes a structure, not a safety level or an effect. Insulin is a peptide. So is a gray-market vial from an unregulated website. Same category, opposite realities. When someone sells you something because “it’s a peptide,” that’s the beginning of the questions — not the answer.

Two weeks out, the FDA’s own scientists broke ranks — quietly

Ahead of the July 23–24 hearing on whether seven peptides can be legally compounded, the FDA’s own reviewers published their evidence assessment — and flagged potential safety concerns and a lack of consistent human data across the compounds under review (BPC-157, TB-500, MOTS-C and others). That’s notable because the political momentum runs the other way: Health Secretary RFK Jr. has publicly championed these peptides and promised to reverse the restrictions. So you now have the unusual situation of the agency’s scientists and its leadership pointing in different directions heading into the vote. Worth watching whose read wins.

The most sensible thing anyone’s said about this — from a former Surgeon General. In a STAT op-ed this week, Dr. Jerome Adams (US Surgeon General 2017–2021) argued for a “structured, clinician-guided third way”: neither an unregulated gray-market free-for-all, nor a blanket ban that just drives people to sketchy overseas suppliers. His point is one we’ve made here repeatedly — people are already using these peptides in large numbers, mostly from unregulated sources, so the honest question isn’t “should they exist” but “how do we make access safer and better-informed.” A regulated, tested, prescription-based supply with real labeling and safety data beats the current Wild West. That’s the adult-in-the-room position, and it’s good to see it in a major outlet.

This week’s real story cuts across weight, aging, and recovery at once: GLP-1s and your muscle

Long-term data now makes something clear — up to 40% of the weight lost on high-efficacy GLP-1 medications isn’t fat, it’s lean body mass (muscle). New research presented at the big diabetes conference this year is racing to address it: a combination therapy (bimagrumab + semaglutide) that preserves muscle while cutting fat, and even biosensors to track muscle loss in real time. Meanwhile, a separate UC San Diego trial gave the first randomized evidence that semaglutide may slow biological aging markers — genuinely striking, though it was in a specific population (adults with HIV) and shouldn’t be over-read.

The honest synthesis — because this is where the hype and the fear both get it wrong: GLP-1s are a genuinely powerful, well-evidenced tool and the muscle-loss signal is real, especially for older adults, where some data shows reduced grip strength and accelerated sarcopenia with long-term use. The answer isn’t to fear the drug or to ignore the risk. It’s the same unglamorous foundation we always come back to: resistance training and adequate protein aren’t optional add-ons to a GLP-1 — they’re what determines whether you come out the other side stronger or frailer.

“Is it too late for me?” — the HRT timing myth that refuses to die

As HRT surges back into the conversation, one framing keeps circulating: the “timing window” — the idea that if you’re more than 10 years past menopause, you’ve missed your chance. It gets repeated in headlines, in forums, and sometimes even in exam rooms. And it’s wrong in the way that matters most.

Here’s the accurate version: the benefits of HRT do tend to be greatest when started earlier — within about 10 years of menopause. But it is never too late. Starting later is still protective, and more protective than not starting at all. The “window” is not a door that slams shut; it’s a gradient. If you’re past that early window and have been told (or assumed) that HRT is off the table for you, that’s worth a real, individualized conversation with a clinician who knows your history — not a foregone “too late.”

The gap between “earlier is better” and “later is pointless” is exactly where a lot of women get lost — and exactly the kind of nuance this newsletter exists for.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory and research details current as of writing and subject to change.

← All issues